Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1996 1
2006 2
2007 1
2008 1
2009 1
2010 2
2011 2
2012 1
2014 6
2015 4
2016 8
2017 3
2018 3
2019 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M; Swiss Group of Clinical Cancer Research (SAKK). Hirschmann A, et al. Among authors: matter walstra k. Oral Oncol. 2018 Dec;87:104-110. doi: 10.1016/j.oraloncology.2018.10.032. Epub 2018 Oct 30. Oral Oncol. 2018. PMID: 30527224
Trastuzumab beyond progression: a cost-utility analysis.
Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Matter-Walstra KW, et al. Ann Oncol. 2010 Nov;21(11):2161-2168. doi: 10.1093/annonc/mdq250. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20444849 Free article.
End-of-life costs of medical care for advanced stage cancer patients.
Kovacević A, Dragojević-Simić V, Rancić N, Jurisević M, Gutzwiller FS, Matter-Walstra K, Jakovljević M. Kovacević A, et al. Among authors: matter walstra k. Vojnosanit Pregl. 2015 Apr;72(4):334-41. doi: 10.2298/vsp1504334k. Vojnosanit Pregl. 2015. PMID: 26040179
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK). Panje CM, et al. Among authors: matter walstra k. Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10. Radiother Oncol. 2018. PMID: 30104008 Clinical Trial.
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Matter-Walstra K, Schwenkglenks M, Dedes KJ. Matter-Walstra K, et al. Breast Cancer Res Treat. 2017 Jun;163(3):635. doi: 10.1007/s10549-017-4209-5. Epub 2017 Mar 21. Breast Cancer Res Treat. 2017. PMID: 28321586 No abstract available.
35 results